Format

Send to

Choose Destination
Adv Drug Deliv Rev. 2012 Oct;64(13):1508-21. doi: 10.1016/j.addr.2012.08.014. Epub 2012 Sep 5.

RNAi-based nanomedicines for targeted personalized therapy.

Author information

1
Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S. Wise Faculty of Life Science, Israel.

Abstract

RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved-safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting "omics" discipline to personalize RNAi-based therapeutics.

PMID:
22975009
DOI:
10.1016/j.addr.2012.08.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center